CLGN (CollPlant Biotechnologies) Research & Development: $7.76 Mil (TTM As of Mar. 2026)


CLGN CollPlant Biotechnologies Ltd CLGN
35 GF Score
Price $0.34
GF Value $0.29
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Research & Development?

CollPlant Biotechnologies CLGN -2.46% 35 Research & Development is $7.76 Mil as of Mar. 2026. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CollPlant Biotechnologies's Research & Development for the three months ended in Mar. 2026 was $1.68 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $7.76 Mil.

CollPlant Biotechnologies  (NAS:CLGN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CollPlant Biotechnologies Research & Development Related Terms

CollPlant Biotechnologies Research & Development Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Research & Development Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.63 10.26 10.48 10.52 8.19

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.11 2.01 2.09 1.98 1.68
CLGN
35GF Score
CollPlant Biotechnologies Ltd CLGN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $7.76 Mil mean?
CollPlant Biotechnologies (CLGN) has a Research & Development of $7.76 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on CollPlant Biotechnologies and its competitors.
Is CollPlant Biotechnologies' Research & Development too high?
CollPlant Biotechnologies' current Research & Development is $7.76 Mil. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Research & Development compare to CPMV and TCRT?
CollPlant Biotechnologies' Research & Development of $7.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current Research & Development is $7.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.34 — trading 17.3% above its estimated fair value. The current Research & Development is $7.76 Mil. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Research & Development is $7.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of $0.34 is trading 17.3% above its estimated GF Value™ of $0.29. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for CLGN:

  • Research & Development: $7.76 Mil
  • GF Value™: $0.29 vs. price of $0.34 (17.3% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Other Exchanges CPT:Germany
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score

Get the complete analysis for CLGN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$0.29
GF Value